93 related articles for article (PubMed ID: 3119196)
1. A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
Arteaga CL; Forseth BJ; Clark GM; Von Hoff DD
Cancer Res; 1987 Dec; 47(23):6248-53. PubMed ID: 3119196
[TBL] [Abstract][Full Text] [Related]
2. Use of a radiometric system to screen for antineoplastic agents: correlation with a human tumor cloning system.
Von Hoff DD; Forseth B; Warfel LE
Cancer Res; 1985 Sep; 45(9):4032-8. PubMed ID: 3928148
[TBL] [Abstract][Full Text] [Related]
3. New screening system for selection of anticancer drugs for treatment of human colorectal cancer.
Scheithauer W; Clark GM; Moyer MP; Von Hoff DD
Cancer Res; 1986 Jun; 46(6):2703-8. PubMed ID: 3698003
[TBL] [Abstract][Full Text] [Related]
4. A sensitive assay for the evaluation of cytotoxicity and its pharmacologic modulation in human solid tumor-derived cell lines exposed to cancer-therapeutic agents.
Mirzayans R; Andrais B; Scott A; Tessier A; Murray D
J Pharm Pharm Sci; 2007; 10(2):298s-311s. PubMed ID: 17718933
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
6. Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines.
Stoeger SM; Cowan KH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):807-18. PubMed ID: 18661133
[TBL] [Abstract][Full Text] [Related]
7. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
9. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.
Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H
Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427
[TBL] [Abstract][Full Text] [Related]
10. A new method for in vitro chemosensitivity assay: inhibition of metabolic CO2 production.
Kurnick NB; Coats HA; de Jesus I
Biomed Pharmacother; 1983; 37(7):351-3. PubMed ID: 6421339
[TBL] [Abstract][Full Text] [Related]
11. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
12. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
[TBL] [Abstract][Full Text] [Related]
13. Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors.
Vassilev LT; Kazmer S; Marks IM; Pezzoni G; Sala F; Mischke SG; Foley L; Berthel SJ
Anticancer Drug Des; 2001 Feb; 16(1):7-17. PubMed ID: 11762646
[TBL] [Abstract][Full Text] [Related]
14. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
15. Selection of chemotherapy for patient treatment utilizing a radiometric versus a cloning system.
Von Hoff DD; Forseth BJ; Turner JN; Clark GM; Warfel LE
Int J Cell Cloning; 1986 Jan; 4(1):16-26. PubMed ID: 3950456
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation on different human cancer cell lines of novel colchicine analogs.
De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Danieli B; Capelli G; Mancuso S; Scambia G
Oncol Res; 1999; 11(3):145-52. PubMed ID: 10527074
[TBL] [Abstract][Full Text] [Related]
18. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity.
Solomon VR; Hu C; Lee H
Bioorg Med Chem; 2009 Nov; 17(21):7585-92. PubMed ID: 19804979
[TBL] [Abstract][Full Text] [Related]
19. In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.
Geromichalos GD; Katsoulos GA; Hadjikostas CC; Kortsaris AH; Kyriakidis DA
Drugs Exp Clin Res; 1998; 24(2):93-104. PubMed ID: 9675550
[TBL] [Abstract][Full Text] [Related]
20. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
